NHS glaucoma care in the UK in 2026 involves two waits: a routine referral takes about 6 to 20 weeks for a first consultant appointment against the 18-week Referral-to-Treatment target, and, more importantly, ongoing monitoring follow-ups sit outside RTT and are frequently delayed. Because glaucoma optic-nerve damage is irreversible, delayed follow-up is a recognised patient-safety risk that has been linked to avoidable sight loss. Urgent referrals are seen within days; acute angle-closure is a same-day emergency. If your monitoring is slipping, private consultant assessment is available within 1–2 weeks, with SLT laser from £950.
Fast answer: how long is the NHS glaucoma wait in 2026?
Glaucoma is the leading cause of preventable irreversible blindness in the UK, and around 700,000 people in England are living with it — roughly half undiagnosed. Ophthalmology is the single busiest outpatient specialty in the NHS, which is why capacity is tight. In 2026 a routine glaucoma referral typically waits 6 to 20 weeks for a first consultant appointment (against an 18-week RTT target in England), shortest where virtual glaucoma clinics and independent-sector units operate and longest in Wales and Northern Ireland.
Honest one-liner: for glaucoma the risk is rarely the wait for the first appointment — it is the wait for the next monitoring appointment. Glaucoma damage cannot be reversed, so a follow-up review that slips by months can allow undetected progression. That is the specific reason some patients choose private monitoring, not because the treatment differs.
Region-by-region NHS glaucoma waiting times (2026 indicative)
Indicative routine NHS glaucoma referral-to-first-appointment waits by UK region in 2026, drawn from published ophthalmology RTT and outpatient statistics. Glaucoma is managed within the hospital eye service, so these follow ophthalmology outpatient waits; local variation within each region is wide — check your specific trust or health board.
Most UK regions’ routine glaucoma first-appointment waits reach beyond the 18-week RTT target — and repeat monitoring follow-ups, where sight loss is actually risked, sit outside RTT entirely. Private assessment runs 1–2 weeks.
| Region / nation | Typical first-appointment wait (2026) | Notes |
|---|---|---|
| London & South East (England) | 6–16 weeks | High independent-sector capacity; many virtual glaucoma clinics |
| North West (England) | 7–18 weeks | Manchester & Liverpool high-volume ophthalmology units |
| South West (England) | 8–18 weeks | Bristol, Plymouth, Exeter hubs; rural patches longer |
| Midlands (England) | 8–20 weeks | Birmingham & Nottingham glaucoma services; monitoring backlog pressure |
| North East & Yorkshire (England) | 8–20 weeks | Newcastle, Leeds, Sheffield; some virtual-clinic triage |
| Scotland (urban boards) | 8–20 weeks | National Treatment Centres absorbing outpatient volume |
| East of England | 10–22 weeks | Norfolk & Suffolk historically longer; recovery improving |
| Wales (Cardiff / South East) | 12–24 weeks | Cardiff & Vale, Aneurin Bevan urban services |
| Scotland (Highland / islands / rural) | 12–26 weeks | Geography limits clinic access |
| Wales (West / North) | 14–30 weeks | Hywel Dda & Betsi Cadwaladr historically longest |
| Northern Ireland | 24–52+ weeks | Longest UK outpatient waits; monitoring intervals frequently exceeded |
These are indicative typical ranges for a routine referral drawn from publicly published 2025–2026 NHS ophthalmology waiting-list statistics; your local trust or board may be faster or slower, and monitoring follow-ups are a separate issue covered next.
The monitoring backlog — the wait that actually threatens sight
Unlike cataract, most glaucoma is not treated by a single operation you wait once for. It is a lifelong condition managed by regular monitoring — pressure checks, optic-nerve imaging (OCT) and visual-field tests — with treatment adjusted over time. The danger in the NHS is not usually the first appointment; it is the follow-up backlog, because review appointments are not counted in the 18-week RTT target and can therefore be deferred when clinics are full.
- Why it matters — glaucoma optic-nerve damage is permanent. If pressure rises or the disease progresses between overdue reviews, the sight already lost cannot be recovered.
- A recognised safety issue — national patient-safety investigations in England have specifically examined the lack of timely monitoring of glaucoma patients and linked delayed follow-up to avoidable, irreversible sight loss.
- How trusts are responding — virtual glaucoma clinics, optometrist-led monitoring, risk-stratification and referral-refinement schemes are being used to protect the highest-risk patients first.
- What you can do — if you are overdue for a glaucoma review, or notice any change in your vision, do not simply wait; contact your eye clinic, GP or the trust Patient Advice and Liaison Service (PALS) and ask for your monitoring interval and where you are on the list.
Monitoring overdue or slipping? A private consultant glaucoma assessment includes intra-ocular pressure, OCT optic-nerve imaging and visual fields, usually within 1–2 weeks — so you know your pressure and progression are being watched on a reliable interval.
Book an assessmentThe 18-week Referral-to-Treatment (RTT) standard — and its glaucoma blind spot
In England the RTT standard says 92% of patients on a non-emergency referral pathway should start consultant-led treatment within 18 weeks of referral. The clock starts when the referral arrives and stops at first definitive treatment. For glaucoma, first treatment might be starting drops, SLT laser or surgery.
- Clock start — receipt of the referral at the hospital eye service.
- Clock stop — first definitive treatment (drops, SLT or surgery), or a decision that treatment is not yet needed.
- The blind spot — once you are a known glaucoma patient, your repeat monitoring reviews are not covered by the 18-week RTT clock, so a delayed follow-up does not breach RTT even though it is the appointment that protects your sight.
- Suspects and stable patients — low-risk glaucoma suspects are often moved to virtual or optometrist-led review, which frees consultant capacity but can lengthen intervals.
Scotland uses a 12-week Treatment Time Guarantee plus the 18-week RTT for outpatient stages; Wales uses 26-week and 36-week planned-care targets; Northern Ireland publishes elective waits separately. These standards govern first treatment — not the ongoing monitoring interval that matters most in glaucoma.
Urgent vs routine NHS glaucoma referral — what gets you fast-tracked
Glaucoma referrals are triaged by risk. The following are typically expedited, seen within days rather than weeks:
- Acute angle-closure glaucoma — sudden painful red eye, haloes, headache, vomiting. A same-day ophthalmic emergency; go to A&E or eye casualty immediately.
- Very high intra-ocular pressure — markedly raised pressure (for example above 30 mmHg) carries a high risk of rapid damage.
- Advanced or rapidly progressing field loss — significant existing damage, or fast change on visual fields or OCT.
- Monocular patient — glaucoma in an only-seeing eye.
- Childhood / congenital glaucoma — always urgent; managed in specialist paediatric services.
Routine cases are low-risk glaucoma suspects, ocular hypertension under control and stable established glaucoma. If your circumstances change — new symptoms, a pressure spike found by your optometrist — tell your GP or optometrist so your referral can be upgraded.
The glaucoma treatment pathway (drops → SLT → MIGS → surgery)
Glaucoma treatment is a ladder, escalating only as needed to lower eye pressure and protect the optic nerve:
- Eye drops — prostaglandin analogues and others lower pressure; effective but depend on daily use.
- SLT laser — 360-degree selective laser trabeculoplasty, recommended by NICE (NG81) as a first-line option for many newly diagnosed patients following the LiGHT trial; quick, repeatable, drop-sparing.
- MIGS — micro-invasive glaucoma surgery (iStent, Hydrus and similar), often combined with cataract surgery for mild-to-moderate glaucoma.
- Filtration surgery — trabeculectomy, PreserFlo microshunt or a drainage tube for advanced or uncontrolled glaucoma.
The same ladder is available on the NHS and privately — the difference is timing and monitoring reliability, not the treatments themselves. See our guides to glaucoma treatment and drops vs SLT vs MIGS vs surgery.
How to check your own NHS glaucoma waiting time
- NHS App / patient portal — many English trusts show your appointment dates, pathway status and RTT clock; look under “Referrals” or “Hospital appointments”.
- Ask for your monitoring interval — for known glaucoma, ask the clinic what interval your consultant set (for example 4 or 6 months) and whether your next review is booked to that date.
- PALS — each NHS trust has a Patient Advice and Liaison Service to query waits and escalate an overdue follow-up.
- Public statistics — NHS England publishes monthly RTT statistics by trust and specialty (Ophthalmology); Public Health Scotland, NHS Wales and HSC NI publish equivalents.
- Right to choose (England) — you can ask your GP or optometrist to refer to any ICB-contracted provider, including faster independent-sector eye units.
UK 2026 private glaucoma treatment prices — itemised
If you choose to go private — most often to secure reliable monitoring or a faster first appointment — typical UK 2026 self-pay fees are:
| Treatment / stage | UK 2026 typical fee | Notes |
|---|---|---|
| Consultant glaucoma assessment (OCT + visual fields) | from £240 | Full diagnostic work-up; often same as first private appointment |
| SLT laser (360°, per treatment) | from £950 | NICE first-line option for many patients; both eyes usually one visit |
| MIGS (iStent / Hydrus, usually with cataract) | from £2,500 | Micro-invasive; commonly combined with cataract surgery |
| Trabeculectomy / PreserFlo / tube | from £4,200 | For advanced or uncontrolled glaucoma |
| Private glaucoma drops (prescription) | ongoing | Same licensed drops as NHS; private script and monitoring |
| NHS | Free | Drops, SLT, MIGS and surgery per the pathway described above |
Prices are an indicative UK CQC-registered sample audited against published 2024–2026 self-pay tariffs, and typically include the consultation, imaging and the procedure; ongoing drops and monitoring are additional. Always ask for a written all-inclusive quotation before treatment. See glaucoma treatment costs, SLT laser cost and glaucoma surgery cost.
Related guides:
- About glaucoma treatment
- Glaucoma: the condition explained
- iStent / MIGS cost
- Trabeculectomy surgery
- Private glaucoma consultation cost
Frequently asked questions
Sources and methodology
- Statutory waiting-list data: NHS England Referral-to-Treatment monthly statistics (Ophthalmology); Public Health Scotland Stage-of-Treatment statistics; NHS Wales RTT and Planned Care statistics; HSC Northern Ireland elective-care statistics.
- Clinical guidance: NICE NG81 (Glaucoma: diagnosis and management); the LiGHT trial (SLT as first-line treatment); Royal College of Ophthalmologists commissioning and glaucoma guidance; Get It Right First Time (GIRFT) Ophthalmology national report.
- Patient safety: national patient-safety investigations into the timeliness of glaucoma monitoring and follow-up in the hospital eye service.
- Editorial review: reviewed by a UK GMC-registered consultant ophthalmic surgeon and Royal College Fellow before publication.
Independent sources we reference: NICE NG81, Royal College of Ophthalmologists, NHS glaucoma and NHS England RTT statistics.
Editorial information · NHS waiting times change month to month and this is not a substitute for personalised medical advice. Always check the official up-to-date source for your specific trust or board.